Yufan, Abound Bio to develop CAR T cell therapies

By The Science Advisory Board staff writers

September 16, 2020 -- Yufan Biotechnologies and Abound Bio have signed a multiyear agreement to find antibodies to direct chimeric antigen receptor (CAR) T cells against cancer targets.

The three-year deal covers incorporating antibodies to 10 cancer targets into a HPK1- (hematopoietic progenitor kinase 1) inhibited CAR T-cell platform. HPK1 promotes T-cell exhaustion, which is a strategy that can be used to improve CAR T-cell immunotherapy.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?